#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14008	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2042	674.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1409	1409	C	777	C,T	756,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25588	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3596	704.9	0	.	n	.	0	T695C	SNP	695	695	T	981	981	C	757	C	744	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25588	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3596	704.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1623	1623	A	848	A,G	819,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25588	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3596	704.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2257	2257	C	761	C,A	740,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25588	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3596	704.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2331	2331	A	737	A	718	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25588	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3596	704.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2883	2883	C	797	C	782	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1652	folP	852	852	100.0	folP.l6.c4.ctg.1	1522	107.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1038	1040	AGC	188;187;187	A;G;C	184;182;182	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4464	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3345	132.1	1	SNP	p	S91F	0	.	.	271	273	TCC	557	559	TCC	145;149;151	T;C,T;C	140;144,1;146	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4464	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3345	132.1	1	SNP	p	D95G	0	.	.	283	285	GAC	569	571	GAC	148;147;148	G;A,G;C	142;139,1;144	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4464	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3345	132.1	1	SNP	p	D95N	0	.	.	283	285	GAC	569	571	GAC	148;147;148	G;A,G;C	142;139,1;144	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1388	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1434	95.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	501	503	ACC	172;172;169	A,G;C;C,T	164,1;168;165,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1388	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1434	95.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	516	518	CAC	169;168;171	C;A,G;C	166;163,1;168	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1388	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1434	95.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	699	701	CAC	178;176;181	C;A,C;C	175;162,1;175	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1388	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1434	95.6	1	SNP	p	G45D	0	.	.	133	135	GGC	519	521	GGC	172;172;170	G;G;C	170;169;166	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	842	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1014	82.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2799	158.1	1	SNP	p	D86N	0	.	.	256	258	GAC	438	440	GAC	148;149;154	G;A;C	146;146;151	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2799	158.1	1	SNP	p	S87R	0	.	.	259	261	AGT	441	443	AGT	154;153;152	A;G;T	151;150;147	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2799	158.1	1	SNP	p	S87I	0	.	.	259	261	AGT	441	443	AGT	154;153;152	A;G;T	151;150;147	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2799	158.1	1	SNP	p	S87W	0	.	.	259	261	AGT	441	443	AGT	154;153;152	A;G;T	151;150;147	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4488	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2799	158.1	1	SNP	p	S88P	0	.	.	262	264	TCC	444	446	TCC	151;153;152	T;C;C	149;151;151	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3528	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2626	133.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1518	1520	GGC	187;179;179	G;G;C,A	181;172;170,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	0	.	p	.	0	E101D	NONSYN	301	303	GAG	661	663	GAT	200;198;195	G;A;T,G	193;194;190,1	.	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1291	1293	GCC	200;200;206	G;C;C	193;193;198	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1294	1296	ATG	203;205;206	A;T;G	196;200;197	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1306	1308	ACC	207;208;208	A;C;C	200;203;202	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1306	1308	ACC	207;208;208	A;C;C	200;203;202	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1807	1809	ACC	183;182;182	A;C;C	172;179;178	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1861	1863	GCG	189;186;181	G;C;G	185;180;177	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1861	1863	GCG	189;186;181	G;C;G	185;180;177	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1984	1986	GGT	145;145;142	G;G;T	138;138;134	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1993	1995	AGC	136;133;130	A;G;C	131;129;126	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	539	3706	penA	1746	1746	99.54	penA.l6.c4.ctg.1	2435	150.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2011	2013	CCG	93;94;89	C,G;C;G,C	85,2;86;72,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5056	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3183	157.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2260	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1773	125.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	547	547	C	154	C,G	140,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	503	505	CAG	179;180;180	C,A;A,G;G	173,1;173,2;176	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	527	529	GGA	198;193;196	G;G,A;A	190;182,1;189	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	788	790	CTT	188;189;192	C;T;T	184;183;187	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	812	814	GGA	189;188;183	G;G;A	183;183;174	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	D171G	NONSYN	511	513	GAT	896	898	GGT	183;182;182	G;G;T,G	176;178;165,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	950	952	AGC	162;161;159	A;G;C	157;155;152	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1016	1016	T	167	T	164	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	1	SNP	p	G120K	0	.	.	358	360	GGT	743	745	GGT	198;195;195	G;G;T	187;189;177	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	1	SNP	p	A121N	0	.	.	361	363	GCC	746	748	GCC	194;191;193	G;C;C	187;184;187	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2576	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1583	161.4	1	SNP	p	A121D	0	.	.	361	363	GCC	746	748	GCC	194;191;193	G;C;C	187;184;187	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9626	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4928	193.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2061	2063	AAT	184;190;191	A;A;T	182;188;189	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1116	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1228	90.4	1	SNP	p	V57M	1	.	.	169	171	ATG	598	600	ATG	225;227;228	A;T;G	221;224;224	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
